Current challenges and unmet medical needs in myelodysplastic syndromes

U Platzbecker, AS Kubasch, C Homer-Bouthiette… - Leukemia, 2021 - nature.com
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

U Platzbecker, P Fenaux, L Adès… - Blood, The Journal …, 2019 - ashpublications.org
The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient
response to treatment challenging. In 2006, the International Working Group (IWG) proposed …

Incidence and burden of the myelodysplastic syndromes

CR Cogle - Current hematologic malignancy reports, 2015 - Springer
Since 2001, cases of myelodysplastic syndromes (MDSs) have been tracked by cancer
registries. Examining registry data in the USA, the reported age-adjusted incidence of MDS …

Health-related quality of life in lower-risk MDS patients compared with age-and sex-matched reference populations: a European LeukemiaNet study

R Stauder, GE Yu, KA Koinig, T Bagguley, P Fenaux… - Leukemia, 2018 - nature.com
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a
relevant patient-reported outcome, which is essential in individualized therapy planning …

Outpatient transfusions for myelodysplastic syndromes

EM Wood, ZK McQuilten - Hematology 2014, the American …, 2020 - ashpublications.org
Patients with myelodysplastic syndromes (MDS) often need extended periods of red blood
cell or platelet transfusion support, with the goal to manage symptoms of anemia and …

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

AM Zeidan, U Platzbecker… - Blood, The Journal …, 2022 - ashpublications.org
Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia
requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of …

Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐and intermediate‐1− risk myelodysplastic syndrome: a systematic …

S Park, P Greenberg, A Yucel, C Farmer… - British journal of …, 2019 - Wiley Online Library
Many patients with lower‐risk myelodysplastic syndrome (MDS) experience anaemia, which
has negative consequences. Erythropoiesis‐stimulating agents (ESA s) and their biosimilars …

[HTML][HTML] Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review

A Mo, M Poynton, E Wood, J Shortt, SJ Brunskill… - Blood Reviews, 2023 - Elsevier
Anemia is common in Myelodysplastic Syndromes (MDS). Different anemia treatments have
been tested in clinical studies, but the full impact on patients' health-related quality of life …

[HTML][HTML] Targeting health-related quality of life in patients with myelodysplastic syndromes–current knowledge and lessons to be learned

EN Oliva, U Platzbecker, P Fenaux, G Garcia-Manero… - Blood reviews, 2021 - Elsevier
Using a range of health-related quality of life (HRQoL) instruments, most–but not all–studies
of myelodysplastic syndromes (MDS) have reported that lower hemoglobin levels and red …

Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria

CP Escalante, S Chisolm, J Song… - Cancer …, 2019 - Wiley Online Library
Background Fatigue is distressing and affects quality of life (QoL) among patients with
myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal …